Skip to main content
padlock icon - secure page this page is secure

Open Access Emerging Viral Infectious Diseases & Oncolytic Viro-Immunotherapy

Download Article:
 Download
(PDF 370.2 kb)
 
The dynamics of climate change, globalisation, urbanisation and viral evolution can lead to the occurrence of outbreaks and the geographical expansion of viral diseases. This is especially true for vector-borne viruses (such as the dengue and zika viruses) and those that require close contact (such as the Ebola and influenza viruses). In addition, blood-borne viruses that are without preventive vaccines, such as HIV and the hepatitis C virus, remain a problem in several parts of the world, especially regions where resources are limited. At the same time, viruses can also be explored as a type of nanomedicine for the treatment of cancers. This presents the exciting possibility of employing nanoscale viral particles as oncolytic agents. To address the range of problems associated with viral diseases, the Molecular Virology and Oncolytics Laboratory (MVOL) has set about targeting viral entry, which could prove useful for developing therapeutic and prophylactic treatments. Such treatments would be particularly effective in the absence of readily available vaccines. Dr Liang-Tzung Lin, a faculty at the Department of Microbiology and Immunology at Taipei Medical University, Taiwan, leads MVOL. His team conducts projects that tackle emerging viral infectious diseases and identify antiviral strategies to preclude viral entry. In addition, he also leads the researchers in engineering viruses with a propensity to selectively target and replicate in cancer cells, and simultaneously stimulate the host antitumor response. The goal is to explore oncolytic viro-immunotherapy as a treatment to combat cancers. Together, these two themes represent the main focus of MVOL.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ANTIVIRALS; BLOOD-BORNE VIRUSES; EMERGING VIRUSES; FLAVIVIRUSES; HEPATITIS C VIRUS; HOST FACTORS; MEASLES VIRUS; MOLECULAR VIROLOGY; THERAPEUTIC AND PROPHYLACTIC TREATMENTS; VIRAL DISEASES; VIRAL ENTRY; VIRAL ONCOLYTICS; VIRAL PATHOGENESIS

Document Type: Research Article

Publication date: December 1, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more